Small-cap investors may wonder to themselves what is the importance of data with respect to the emerging cannabis industry? The key point here is that cannabis is an emerging industry, and still a relatively new consumer product – at least in the legitimate marketplace.
As an emerging industry, accurate and plentiful data plays a vital role in the efficient evolution of this industry. Which cannabis strains provide the best medicinal results for patients? Which medical conditions respond best to cannabis as a medical therapy option? The database pertaining to the medicinal use of cannabis which has been compiled by Canabo Medical Inc. (TSX: V.CMM, OTCQB: CAMDF, Forum) helps to answer these questions, and many more.
What is meant by Canabo Medical’s “big data”?
- Data collected on more than 15,000 medicinal cannabis patients
- Up to 400 data points compiled per patient
- Includes data on the patient’s medical history, symptoms, and the efficacious results of cannabis therapy, evaluated after 3- and 6-month intervals
The Globe & Mail estimates there will be more than 400,000 licensed users of medicinal marijuana in Canada by 2024. It can potentially require millions of R&D dollars and a considerable investment of time/energy to develop a new product. How do competing cannabis companies acquire a competitive edge in this race to be first?
Canabo’s “big data” can potentially reduce both costs and time in bringing new-and-efficacious medicinal cannabis products to market. Already, ten of Canada’s licensed producers have commissioned Canabo for access to their Big Data.
Industry heavy-weights like Aurora Cannabis, Aphria, and OrganiGram have been the leaders in trading volume on the Venture Exchange in recent weeks. Combined, these companies have more than $1.5 billion in market cap. There are big bucks floating around the legal cannabis space at the moment, and a strong profit motive to utilize Canabo’s industry-leading cannabis database.
Pinnacle Digest sat down with Canabo Medical’s Chairman Neil Smith and newly-appointed Medical Director Michael Verbora to discuss current developments and the future potential of the Company’s operations in the medicinal marijuana space.
www.canabocorp.com/
FULL DISCLOSURE: Canabo Medical Inc is a paid client of Stockhouse Publishing.